A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study.

Int J Cancer · 2021 · PMC7894541 · PMID 32949150

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significanceP = .060so close (0.05 < p ≤ 0.1)

Interestingly, a stratification by 10% iTF did not reach statistical significance ( P = .060), but after adjustment for the covariates' age and sex, a significant effect was observed ( P = .041, HR = 2.4, 95% CI: 1.1‐5.7) (Figure 3B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.